These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34216176)

  • 81. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
    Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
    Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
    J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 85. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis.
    Zheng W; Quan B; Gao G; Zhang P; Huang L
    Lab Med; 2023 Mar; 54(2):130-141. PubMed ID: 36106407
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Serum circulating free DNA of syncytin-1 as a novel molecular marker for early diagnosis of non-small-cell lung cancer.
    Zhuang X; Qian J; Xia X; Wang Y; Wang H; Jing L; Zhang Y; Zhang Y
    Biomark Med; 2022 Dec; 16(18):1259-1268. PubMed ID: 36861469
    [No Abstract]   [Full Text] [Related]  

  • 89. Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series.
    Peled M; Bar J; Avni L; Chatterji S; Somech D; Dvir A; Soussan-Gutman L; Onn A
    Isr Med Assoc J; 2020 Dec; 22(12):784-787. PubMed ID: 33381953
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
    Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
    BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma.
    Taylor C; Chacko S; Davey M; Lacroix J; MacPherson A; Finn N; Wajnberg G; Ghosh A; Crapoulet N; Lewis SM; Ouellette RJ
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260345
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.
    Qi F; Cao Z; Chen B; Chai Y; Lin J; Ye J; Wei Y; Liu H; Han-Zhang H; Mao X; Feng X; Dong M
    Blood Adv; 2021 Jun; 5(11):2505-2514. PubMed ID: 34047776
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
    Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
    Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.
    Mehrotra M; Singh RR; Chen W; Huang RSP; Almohammedsalim AA; Barkoh BA; Simien CM; Hernandez M; Behrens C; Patel KP; Routbort MJ; Broaddus RR; Medeiros LJ; Wistuba II; Kopetz S; Luthra R
    J Mol Diagn; 2017 Jul; 19(4):514-524. PubMed ID: 28506684
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cell-Free DNA in Oncology: Gearing up for Clinic.
    Ulrich BC; Paweletz CP
    Ann Lab Med; 2018 Jan; 38(1):1-8. PubMed ID: 29071812
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs.
    Xie J; Hu B; Gong Y; He S; Lin J; Huang Q; Cheng J
    J Transl Med; 2023 Dec; 21(1):873. PubMed ID: 38041139
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.